Close Menu

renal cancer

Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.

A Broad Institute-led team found that differences by ancestry could affect not only how cancer develops but also treatment approaches.

Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.

In an AMP Global presentation, Danish Cancer Society Research Center scientists used the test to study urine samples from individuals who developed bladder cancer up to 15 years later.

In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.

A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

Paradigm will use its NGS-based PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib.

Pages

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.